Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agiliti, Inc. stock logo
AGTI
Agiliti
$10.06
$5.07
$18.61
$1.37B1.91.78 million shs26.51 million shs
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$25.59
$25.59
$9.90
$25.61
$2.21B0.191.29 million shs600 shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$46.84
-0.3%
$33.23
$19.45
$53.27
$3.05B2.07616,338 shs490,385 shs
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
$13.82
-1.3%
$13.70
$6.62
$17.67
$1.19B1.27805,750 shs758,049 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agiliti, Inc. stock logo
AGTI
Agiliti
0.00%0.00%0.00%0.00%0.00%
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-0.26%-0.68%+54.84%+37.64%+40.70%
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
-1.45%-2.23%-7.21%-1.69%+90.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agiliti, Inc. stock logo
AGTI
Agiliti
N/AN/AN/AN/AN/AN/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.4594 of 5 stars
4.53.00.00.03.61.70.0
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
0.9395 of 5 stars
2.23.00.00.01.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agiliti, Inc. stock logo
AGTI
Agiliti
0.00
N/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
0.00
N/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.00
Buy$59.8227.72% Upside
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
2.33
Hold$16.6720.62% Upside

Current Analyst Ratings Breakdown

Latest AGTI, DCPH, MD, and KYMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$38.00 ➝ $60.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$49.00 ➝ $79.00
6/2/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$51.00
5/20/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
5/13/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$72.00 ➝ $70.00
5/12/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$47.00 ➝ $44.00
5/12/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$52.00 ➝ $52.00
5/12/2025
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.50 ➝ $16.00
5/8/2025
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$19.00 ➝ $20.00
(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agiliti, Inc. stock logo
AGTI
Agiliti
$1.17B0.00N/A5.76$6.98 per share0.00
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$174.91M12.65N/AN/A$4.38 per share5.84
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$58.89M51.80N/AN/A$7.12 per share6.58
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
$1.98B0.60$2.81 per share4.91$8.91 per share1.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agiliti, Inc. stock logo
AGTI
Agiliti
-$19.42M-$0.14N/A0.00N/A-1.65%6.47%2.53%N/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$146.96M-$3.10N/AN/AN/A-191.26%-24.96%-20.27%8/6/2025 (Estimated)
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
-$60.41M-$1.01N/A10.311.74-4.92%15.47%5.64%8/5/2025 (Estimated)

Latest AGTI, DCPH, MD, and KYMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million
5/6/2025Q1 2025
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
$0.25$0.33+$0.08$0.24$451.44 million$458.36 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agiliti, Inc. stock logo
AGTI
Agiliti
N/AN/AN/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agiliti, Inc. stock logo
AGTI
Agiliti
1.13
1.72
1.34
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/A
4.19
3.94
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.55
8.55
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
0.81
1.60
1.42

Institutional Ownership

CompanyInstitutional Ownership
Agiliti, Inc. stock logo
AGTI
Agiliti
99.12%
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
70.96%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
97.71%

Insider Ownership

CompanyInsider Ownership
Agiliti, Inc. stock logo
AGTI
Agiliti
4.16%
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
4.67%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
0.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agiliti, Inc. stock logo
AGTI
Agiliti
5,800136.08 million130.42 millionOptionable
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
30086.48 million82.44 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17065.12 million54.52 millionOptionable
Pediatrix Medical Group, Inc. stock logo
MD
Pediatrix Medical Group
7,85085.91 million84.16 millionOptionable

Recent News About These Companies

Q2 EPS Forecast for Pediatrix Medical Group Cut by Analyst
Pediatrix Medical Group, Inc. stock logo
Zacks Research Issues Negative Forecast for MD Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Agiliti stock logo

Agiliti NYSE:AGTI

Agiliti, Inc., together with its subsidiaries, provides healthcare technology management and service solutions to the healthcare industry in the United States. The company offers onsite managed services that are comprehensive programs for the management, reprocessing, and logistics of medical equipment at individual facilities and integrated delivery networks to monitor and adjust equipment quantities and availability to address fluctuations in patient census and acuity. It also provides clinical engineering services comprising maintenance, repair, and remediation solutions for various types of medical equipment, including general biomedical equipment, diagnostic imaging equipment, and surgical equipment through supplemental and outsourced offerings. In addition, the company offers equipment solutions, which primarily provide supplemental, peak need, and per-case rental of general biomedical, specialty, and surgical equipment to acute care hospitals and alternate site providers, including premier healthcare institutions and integrated delivery networks. It serves acute care hospitals, health systems and integrated delivery networks and alternate site providers. The company was founded in 1939 and is headquartered in Eden Prairie, Minnesota. Agiliti, Inc. operates as a subsidiary of THL Agiliti LLC.

Deciphera Pharmaceuticals stock logo

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$46.84 -0.12 (-0.26%)
Closing price 06/16/2025 04:00 PM Eastern
Extended Trading
$46.82 -0.03 (-0.05%)
As of 06/16/2025 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Pediatrix Medical Group stock logo

Pediatrix Medical Group NYSE:MD

$13.82 -0.18 (-1.31%)
Closing price 06/16/2025 03:59 PM Eastern
Extended Trading
$13.82 0.00 (-0.01%)
As of 06/16/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals, including pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians, pediatric gastroenterologists; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.